Researchers reported the first Phase 3 completion of an in vivo CRISPR-based therapy at Amsterdam University Medical Center and partner hospitals, marking a late-stage milestone for gene editing in patients. The effort demonstrates that an in vivo CRISPR program can progress through pivotal testing rather than remaining confined to early feasibility. Phase 3 completion is a practical barometer for manufacturing, dosing consistency, and regulatory scrutiny around genome editing risk, including on-target and off-target assessments. It also raises expectations for subsequent efficacy and safety readouts. For the field, the development strengthens the case that gene editing can be translated into registrational timelines—supporting investor and developer confidence in platform scalability and long-term monitoring plans.